Pediatric asthma: An unmet need for more effective, focused treatments

Nikolaos G. Papadopoulos, Adnan Čustović, Michael D. Cabana, Sharon D. Dell, Antoine Deschildre, Gunilla Hedlin, Elham Hossny, Peter Le Souëf, Paolo M. Matricardi, Antonio Nieto, Wanda Phipatanakul, Paulo M. Pitrez, Petr Pohunek, Marcela Gavornikova, Xavier Jaumont, David B. Price

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Background: Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma. Methods: A two-day, face-to-face meeting was held in London, United Kingdom, on October 28 and 29, 2017, involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma. Results: These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non-steroid-based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients. Conclusions: There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real-world evidence studies assessing anti-immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti-IgE and non-steroid-based alternative therapies may delay disease progression, leading to improved clinical outcomes.

Original languageEnglish (US)
Pages (from-to)7-16
Number of pages10
JournalPediatric Allergy and Immunology
Volume30
Issue number1
DOIs
StatePublished - Feb 1 2019
Externally publishedYes

Fingerprint

Asthma
Pediatrics
Therapeutics
Complementary Therapies
Immunoglobulin E
Pragmatic Clinical Trials
Passive Immunization
Practice Guidelines
Disease Progression
Monoclonal Antibodies
Guidelines
Safety

Keywords

  • asthma management
  • omalizumab
  • pediatric asthma
  • unmet need

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Immunology

Cite this

Papadopoulos, N. G., Čustović, A., Cabana, M. D., Dell, S. D., Deschildre, A., Hedlin, G., ... Price, D. B. (2019). Pediatric asthma: An unmet need for more effective, focused treatments. Pediatric Allergy and Immunology, 30(1), 7-16. https://doi.org/10.1111/pai.12990

Pediatric asthma : An unmet need for more effective, focused treatments. / Papadopoulos, Nikolaos G.; Čustović, Adnan; Cabana, Michael D.; Dell, Sharon D.; Deschildre, Antoine; Hedlin, Gunilla; Hossny, Elham; Le Souëf, Peter; Matricardi, Paolo M.; Nieto, Antonio; Phipatanakul, Wanda; Pitrez, Paulo M.; Pohunek, Petr; Gavornikova, Marcela; Jaumont, Xavier; Price, David B.

In: Pediatric Allergy and Immunology, Vol. 30, No. 1, 01.02.2019, p. 7-16.

Research output: Contribution to journalReview article

Papadopoulos, NG, Čustović, A, Cabana, MD, Dell, SD, Deschildre, A, Hedlin, G, Hossny, E, Le Souëf, P, Matricardi, PM, Nieto, A, Phipatanakul, W, Pitrez, PM, Pohunek, P, Gavornikova, M, Jaumont, X & Price, DB 2019, 'Pediatric asthma: An unmet need for more effective, focused treatments', Pediatric Allergy and Immunology, vol. 30, no. 1, pp. 7-16. https://doi.org/10.1111/pai.12990
Papadopoulos, Nikolaos G. ; Čustović, Adnan ; Cabana, Michael D. ; Dell, Sharon D. ; Deschildre, Antoine ; Hedlin, Gunilla ; Hossny, Elham ; Le Souëf, Peter ; Matricardi, Paolo M. ; Nieto, Antonio ; Phipatanakul, Wanda ; Pitrez, Paulo M. ; Pohunek, Petr ; Gavornikova, Marcela ; Jaumont, Xavier ; Price, David B. / Pediatric asthma : An unmet need for more effective, focused treatments. In: Pediatric Allergy and Immunology. 2019 ; Vol. 30, No. 1. pp. 7-16.
@article{c11847857fc643ec84b77c8cf2db5edc,
title = "Pediatric asthma: An unmet need for more effective, focused treatments",
abstract = "Background: Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma. Methods: A two-day, face-to-face meeting was held in London, United Kingdom, on October 28 and 29, 2017, involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma. Results: These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non-steroid-based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients. Conclusions: There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real-world evidence studies assessing anti-immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti-IgE and non-steroid-based alternative therapies may delay disease progression, leading to improved clinical outcomes.",
keywords = "asthma management, omalizumab, pediatric asthma, unmet need",
author = "Papadopoulos, {Nikolaos G.} and Adnan Čustović and Cabana, {Michael D.} and Dell, {Sharon D.} and Antoine Deschildre and Gunilla Hedlin and Elham Hossny and {Le Sou{\"e}f}, Peter and Matricardi, {Paolo M.} and Antonio Nieto and Wanda Phipatanakul and Pitrez, {Paulo M.} and Petr Pohunek and Marcela Gavornikova and Xavier Jaumont and Price, {David B.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1111/pai.12990",
language = "English (US)",
volume = "30",
pages = "7--16",
journal = "Pediatric Allergy and Immunology",
issn = "0905-6157",
publisher = "Blackwell Munksgaard",
number = "1",

}

TY - JOUR

T1 - Pediatric asthma

T2 - An unmet need for more effective, focused treatments

AU - Papadopoulos, Nikolaos G.

AU - Čustović, Adnan

AU - Cabana, Michael D.

AU - Dell, Sharon D.

AU - Deschildre, Antoine

AU - Hedlin, Gunilla

AU - Hossny, Elham

AU - Le Souëf, Peter

AU - Matricardi, Paolo M.

AU - Nieto, Antonio

AU - Phipatanakul, Wanda

AU - Pitrez, Paulo M.

AU - Pohunek, Petr

AU - Gavornikova, Marcela

AU - Jaumont, Xavier

AU - Price, David B.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background: Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma. Methods: A two-day, face-to-face meeting was held in London, United Kingdom, on October 28 and 29, 2017, involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma. Results: These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non-steroid-based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients. Conclusions: There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real-world evidence studies assessing anti-immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti-IgE and non-steroid-based alternative therapies may delay disease progression, leading to improved clinical outcomes.

AB - Background: Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma. Methods: A two-day, face-to-face meeting was held in London, United Kingdom, on October 28 and 29, 2017, involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma. Results: These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non-steroid-based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients. Conclusions: There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real-world evidence studies assessing anti-immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti-IgE and non-steroid-based alternative therapies may delay disease progression, leading to improved clinical outcomes.

KW - asthma management

KW - omalizumab

KW - pediatric asthma

KW - unmet need

UR - http://www.scopus.com/inward/record.url?scp=85056461048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056461048&partnerID=8YFLogxK

U2 - 10.1111/pai.12990

DO - 10.1111/pai.12990

M3 - Review article

C2 - 30312503

AN - SCOPUS:85056461048

VL - 30

SP - 7

EP - 16

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

SN - 0905-6157

IS - 1

ER -